Table 6.VI.
Phase III RTOG-1016 trial.
| Cisplatin | Cetuximab | ||
|---|---|---|---|
| 5-years OS | 84.6% | 77.9% | p = 0.0163 |
| Progression-free survival | 78.4% | 67.3% | p = 0.0002 |
| Locoregional failure | 9.9% | 17.3% | p = 0.0005 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.